Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Faiza Khemissa-Akouz

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Cancer Control : Journal of the Moffitt Cancer Center|September 21, 2024
Comparative Efficacy and Long-Term Oncological Safety of Extended Right Hemicolectomy Versus Left Colectomy for Splenic Flexure Adenocarcinoma: A Systematic Review and Meta-AnalysisMohamed Ali Chaouch, Bassem Krimi, Amine Gouader, et al.
The Oncologist|January 15, 2026
The BEVATOMOX phase II trial: raltitrexed/oxaliplatin/bevacizumab vs mFOLFOX6/bevacizumab in 2nd-line metastatic colorectal cancerEmmanuelle Samalin, Hélène Senellart, Simon Thezenas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2025
Impact of Lean Body Mass-Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX TrialEric Assenat, Meher Ben Abdelghani, Sophie Gourgou, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 14, 2022
Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49Simon Pernot, Olivier Pellerin, Laurent Mineur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2021
Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II StudyJean Marc Phelip, Jérôme Desrame, Julien Edeline, et al.
European Journal of Cancer (Oxford, England : 1990)|August 28, 2025
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (PRODIGE 62-FFCD 1701-OESIRI)David Tougeron, Laurent Mineur, Aziz Zaanan, et al.
European Journal of Cancer (Oxford, England : 1990)|July 6, 2020
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX)Yves Rinaldi, Anne-Laure Pointet, Faiza Khemissa Akouz, et al.
The Lancet. Gastroenterology & Hepatology|June 22, 2026
Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trialPhilippe Merle, Jean-Frederic Blanc, Karine Le Malicot, et al.
Journal of Hepatology|May 25, 2019
Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinomaJean-Louis Jouve, Thierry Lecomte, Olivier Bouché, et al.
The Lancet. Oncology|April 26, 2025
TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trialAziz Zaanan, Olivier Bouché, Christelle de la Fouchardière, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Cancer Control : Journal of the Moffitt Cancer Center|September 21, 2024
Comparative Efficacy and Long-Term Oncological Safety of Extended Right Hemicolectomy Versus Left Colectomy for Splenic Flexure Adenocarcinoma: A Systematic Review and Meta-AnalysisMohamed Ali Chaouch, Bassem Krimi, Amine Gouader, et al.
The Oncologist|January 15, 2026
The BEVATOMOX phase II trial: raltitrexed/oxaliplatin/bevacizumab vs mFOLFOX6/bevacizumab in 2nd-line metastatic colorectal cancerEmmanuelle Samalin, Hélène Senellart, Simon Thezenas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2025
Impact of Lean Body Mass-Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX TrialEric Assenat, Meher Ben Abdelghani, Sophie Gourgou, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 14, 2022
Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49Simon Pernot, Olivier Pellerin, Laurent Mineur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2021
Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II StudyJean Marc Phelip, Jérôme Desrame, Julien Edeline, et al.
European Journal of Cancer (Oxford, England : 1990)|August 28, 2025
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (PRODIGE 62-FFCD 1701-OESIRI)David Tougeron, Laurent Mineur, Aziz Zaanan, et al.
European Journal of Cancer (Oxford, England : 1990)|July 6, 2020
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX)Yves Rinaldi, Anne-Laure Pointet, Faiza Khemissa Akouz, et al.
The Lancet. Gastroenterology & Hepatology|June 22, 2026
Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trialPhilippe Merle, Jean-Frederic Blanc, Karine Le Malicot, et al.
Journal of Hepatology|May 25, 2019
Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinomaJean-Louis Jouve, Thierry Lecomte, Olivier Bouché, et al.
The Lancet. Oncology|April 26, 2025
TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trialAziz Zaanan, Olivier Bouché, Christelle de la Fouchardière, et al.
Pageof 2